68Ga-FAPI PET/CT in Liver Fibrosis Patients

• Status: Recruiting
• Trial end date: 2023-12-30
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis and prognosis in liver fibrosis disease.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital of Fujian Medical University

Criteria

Inclusion Criteria:

• adult patients (aged 18 years or order)

• patients with suspected or new diagnosed or previously treated liver fibrosis (supporting evidence may include TE, BBI, MRI, CT and pathology report)

• patients who had scheduled 68Ga-FAPI-04 PET/CT scan

• patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee

Exclusion Criteria:

• patients without liver fibrosis lesions

• patients with pregnancy

• the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent